ABBV-295 for Obesity or Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Recruiting
Phase 2
Interventional Study
Obesity
Overweight
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 360 (estimated)
- Sponsor
- AbbVie · Industry
Who this trial is looking for
This trial is looking for adults with obesity or overweight who have weight-related health issues. Participants will receive injections of either the study drug ABBV-295 or a placebo for 52 weeks, and their progress will be monitored through regular visits and assessments.
Are You a Good Fit for This Trial?
You may be able to join if
- I have a BMI of 30 or higher
- I have a BMI between 27 and 30 and have a weight-related health issue
You may not be able to join if
- I have lost or gained more than 5% of my body weight in the last 3 months
- I have a hemoglobin A1c level of 6.5% or higher
- I have high fasting glucose or random glucose levels
- I have a history of type 1 or type 2 diabetes
- I have taken any medication for obesity or weight management in the last 180 days
- I have had serious cardiovascular issues in the last 180 days
- I have a disease or condition that poses a risk or may affect my participation
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight with weight-related comorbidities.
ABBV-295 is an investigational long-acting amylin analog being devel…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* BMI ≥ 30.0 kg/m2 at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) OR
* BMI ≥ 27.0 to \< 30.0 kg/m2 at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) with at least one of the fo…
Contacts